Zota Health Care Ltd (ZOTA) share price, results, shareholding

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	45	47	50	56	67	72	97	104	129	143	163	174
Expenses	41	44	51	58	68	78	95	100	123	143	154	185
Operating Profit	4	3	-1	-1	-1	-6	2	4	6	-0	9	-12
OPM %	10%	7%	-3.0%	-2.2%	-1.3%	-8%	2.5%	3.8%	4.9%	-0.3%	5%	-7%
Other Income	0	0	0	0	1	1	1	1	2	2	-3	2
Interest	1	1	2	3	3	2	3	3	4	5	5	6
Depreciation	5	5	7	8	10	11	14	15	19	22	27	28
Profit before tax	-1	-3	-10	-12	-13	-18	-14	-13	-14	-26	-26	-44
Tax %	49%	7%	-27%	5%	-4%	2%	-10%	5%	13%	14%	-45%	1%
Net Profit	-2	-3	-7	-13	-12	-19	-13	-14	-16	-30	-14	-44
EPS in Rs	-0.64	-1.14	-2.68	-4.79	-4.41	-6.78	-4.50	-4.81	-5.20	-8.73	-4.09	-12.58

	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	38	50	56	85	95	106	131	139	180	292	538	609
Expenses	33	43	47	77	90	105	116	132	173	298	520	606
Operating Profit	5	6	8	8	5	1	15	7	8	-6	19	3
OPM %	13%	13%	15%	9%	4.8%	0.6%	11%	5%	4.2%	-2.0%	3.4%	0.5%
Other Income	0	0	0	2	2	2	2	2	1	2	1	3
Interest	1	1	1	0	0	0	0	3	5	11	17	20
Depreciation	1	1	2	1	2	3	4	12	20	43	82	96
Profit before tax	3	5	6	8	4	-0	12	-5	-16	-58	-80	-110
Tax %	33%	33%	33%	29%	29%	-41%	28%	23%	-11%	-2%	-7%
Net Profit	2	3	4	6	3	-0	9	-6	-14	-57	-74	-104
EPS in Rs	1.43	1.85	2.12	2.26	1.12	-0.09	3.54	-2.29	-5.55	-19.70	-21.35	-30.60
Dividend Payout %	50%	38%	34%	32%	90%	-1,170%	42%	-44%	-18%	-5%	-5%

	10 Years	5 Years	3 Years	TTM	1 Year	Last Year
Compounded Sales Growth	%	38%	57%	79%
Compounded Profit Growth	%	%	%	-69%
Stock Price CAGR	%	27%	50%		-7%
Return on Equity	%	-16%	-20%			-15%

	Mar 2011	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	7	10	12	14	18	25	25	25	25	26	29	35
Reserves	5	3	4	4	51	44	42	64	55	64	195	659
Borrowings	3	6	5	5	0	0	0	15	45	95	140	270
Other Liabilities	5	10	14	17	21	20	19	35	33	43	76	167
Total Liabilities	20	29	35	40	90	88	85	139	158	228	439	1,131
Fixed Assets	8	10	9	8	10	15	14	29	62	103	185	369
CWIP	0	0	0	0	2	0	0	0	3	5	6	15
Investments	0	0	0	0	16	14	10	33	8	5	54	264
Other Assets	12	19	26	32	63	59	61	77	85	116	193	483
Total Assets	20	29	35	40	90	88	85	139	158	228	439	1,131

	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	3	5	-3	6	-1	13	-2	-6	-50	-82
Cash from Investing Activity	-1	-1	9	-4	4	-27	15	-13	-92	-330
Cash from Financing Activity	-2	-4	-6	-3	-2	14	-14	19	145	503
Net Cash Flow	0	0	-1	-1	1	1	-1	-0	3	92
Free Cash Flow	2	4	-6	-1	-2	10	-13	-23	-96	-208
CFO/OP	78%	81%	-12%	147%	-134%	115%	2%	-59%	811%	-380%

	Mar 2011	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	75	71	79	77	95	112	99	102	73	55	51	50
Inventory Days	122	141	134	175	208	139	140	121	183	201	277	324
Days Payable	77	90	0	0	104	82	77	78	116	126	111	176
Cash Conversion Cycle	120	123	212	251	199	169	161	145	140	131	217	198
Working Capital Days	102	70	78	80	175	152	143	108	111	75	100	84
ROCE %		20%		32%		6%	-2%	15%	-2%	-7%	-17%	-8%

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	66.16%	66.15%	66.15%	64.44%	62.40%	62.02%	59.72%	57.42%	55.81%	50.64%	49.38%	49.38%
FIIs	0.02%	0.00%	0.00%	0.01%	0.01%	0.24%	0.87%	3.82%	3.49%	8.09%	8.21%	7.92%
DIIs	0.00%	0.00%	0.00%	0.00%	0.99%	1.03%	3.08%	4.25%	4.95%	7.22%	6.40%	6.75%
Public	33.83%	33.85%	33.85%	35.55%	36.60%	36.71%	36.33%	34.52%	35.75%	34.06%	36.00%	35.96%
No. of Shareholders	7,285	7,589	7,435	7,661	8,937	9,763	10,389	10,354	11,855	13,185	14,005	14,678

Fundamentals

Market Cap₹ 4,503 Cr.

Current Price₹ 1,300

Book Value₹ 200

ROCE-8.47 %

ROE-15.0 %

Dividend Yield0.08 %

Face Value₹ 10.0

Compounded Sales Growth (TTM)79%

Compounded Profit Growth (TTM)-69%

Consolidated figures.

Valuation

Market capRs 4,391 Cr

Enterprise valueRs 4,566 Cr

Price to book6.33x

Price to sales7.21x

EV / EBITDA818.21x

EV / sales7.50x

Earnings yield-2.35%

Dividend yield0.08%

P/B, 3-year average9.75x

P/E, 5-year average84.04x

P/B, 5-year average9.29x

Profitability

Operating margin (excl. other income)3.44%

Operating margin (incl. other income)3.71%

EBITDA margin0.92%

Pre-tax margin-18.14%

Net profit margin-16.95%

Net margin, latest quarter-25.09%

ROE-16.12%

ROCE-9.41%

ROA-9.42%

ROE, 3-year average-22.98%

ROCE, 3-year average-11.28%

ROA, 3-year average-11.25%

ROE, 5-year average-12.86%

ROCE, 5-year average-4.15%

ROA, 5-year average-5.94%

ROIC (approx.)-9.61%

Tax rate7.22%

Other income / net worth0.21%

Growth

Sales growth (latest year)84.39%

Sales CAGR, 3 years56.91%

Sales CAGR, 5 years38.38%

Sales growth QoQ6.39%

Sales growth YoY (latest quarter)67.60%

Per share

EPS (TTM)Rs -29.79

EPS (latest year)Rs -21.35

EPS (latest quarter)Rs -12.58

EPS, 3-year averageRs -15.53

EPS, 5-year averageRs -9.07

Book value per shareRs 200.24

Sales per shareRs 175.75

Cash flow per shareRs -23.63

Free cash flow per shareRs -60.06

Dividend per share (latest year)Rs 1.00

Dividend per share, 3-year averageRs 1.00

Dividend per share, 5-year averageRs 1.10

Dividends

Dividend payout, 5-year average42.31%

Efficiency

Asset turnover0.48x

Fixed asset turnover1.46x

Inventory turnover1.19x

Inventory days306 days

Debtor days50 days

Debtors turnover7.32x

Creditor days176 days

Cash conversion cycle198 days

Working capital days84 days

Leverage

Total debtRs 270 Cr

Cash and bankRs 96 Cr

Net debtRs 175 Cr

Debt to equity0.39x

Net debt / EBITDA31.34x

Interest coverage-4.39x

Current ratio (filing 2026-03-31)1.93x

Quick ratio (filing 2026-03-31)1.11x

Trade payables (filing 2026-03-31)Rs 105 Cr

Owners' fund to total sources61.31%

Debt to assets23.91%

Cash flow

Cash from Operating Activity (latest year)Rs -82 Cr

Cash from Investing Activity (latest year)Rs -330 Cr

Cash from Financing Activity (latest year)Rs 503 Cr

Net Cash Flow (latest year)Rs 92 Cr

Free cash flow (latest year)Rs -208 Cr

FCFE (approx.: FCF + change in debt)Rs -77 Cr

Statement figures

Net sales (TTM)Rs 609 Cr

Net sales (latest year)Rs 538 Cr

Sales (latest quarter)Rs 174 Cr

Operating profit excl. other income (latest year)Rs 19 Cr

Operating profit (latest quarter)Rs -12 Cr

Other income (TTM)Rs 3 Cr

EBITDA (TTM)Rs 6 Cr

PBDT (TTM)Rs -15 Cr

Profit before tax (TTM)Rs -110 Cr

Tax (latest year)Rs -6 Cr

Net profit (TTM)Rs -103 Cr

Net profit (latest year)Rs -74 Cr

Net profit (latest quarter)Rs -44 Cr

Depreciation (TTM)Rs 96 Cr

Depreciation (latest quarter)Rs 28 Cr

Interest (TTM)Rs 20 Cr

Cost of goods sold (latest year)Rs 230 Cr

Total expenditure (latest year)Rs 520 Cr

Total income (latest year)Rs 540 Cr

Share capitalRs 35 Cr

ReservesRs 659 Cr

Shareholders' fundsRs 693 Cr

Total assetsRs 1,131 Cr

Net blockRs 369 Cr

Capital work in progressRs 15 Cr

InvestmentsRs 264 Cr

ReceivablesRs 74 Cr

InventoryRs 193 Cr

Other liabilitiesRs 167 Cr

Shares outstanding (crore)3.46

Ownership

Promoter holding49.38% (-8.04 in a year)

Computed by MarketFriction from the consolidated statements. Returns use average balances.

P/B 6.33 is at the 1th percentile (median 18.81).

Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.

Period	ZOTA	Nifty 50	Difference
1 week	-5.8%	-2.8%	-3.0 pts
1 month	+23.3%	-6.8%	+30.1 pts
3 months	-12.3%	-7.6%	-4.6 pts
6 months	+19.1%	+0.4%	+18.7 pts
1 year	-14.6%	-9.9%	-4.7 pts
2 years	+93.1%	-13.6%	+106.7 pts
3 years	+228.8%	+14.2%	+214.7 pts
5 years	+220.4%	+27.9%	+192.5 pts

2 mutual fund schemes hold about ₹13 Cr. Over three months 0 bought more and 2 sold (share counts, price move removed).

Fund	Weight	Est. Cr	3m shares
WOC Special Opp Fund	0.53%	10	-25%
WOC Pharma and Healthcare Fund	0.34%	3	-30%

Red flags

F-score 3 of 8

explain	Share dilution Share count up 21% in a year, 37% in three
explain	Debt up, profit down Borrowings up 94% while net profit fell in 2026
look	Repeated losses Net loss in each of the last two years

Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026

Sales ₹174 Cr +67.3% vs Jun 2025. Net loss ₹44 Cr.

Activity

Compare

Company	Mcap (Cr)	P/E	ROCE
Sun Pharmaceutical Industries Ltd	447,476	35.4	20.5 %
Divis Laboratories Ltd	250,363	84.0	22.0 %
Torrent Pharmaceuticals Ltd	186,152	83.4	15.2 %
Zydus Lifesciences Ltd	119,750	24.6	21.1 %
Cipla Ltd	111,430	31.1	15.5 %
Laurus Labs Ltd	106,928	97.8	17.8 %
Mankind Pharma Ltd	105,120	49.3	13.5 %
Dr Reddys Laboratories Ltd	104,494	32.4	13.0 %
Aurobindo Pharma Ltd	97,682	25.8	12.9 %
Lupin Ltd	93,840	15.8	29.9 %
Glenmark Pharmaceuticals Ltd	68,905	22.1	39.8 %
Alkem Laboratories Ltd	62,772	27.6	21.2 %
Biocon Ltd	61,439	84.5	3.61 %
Abbott India Ltd	57,949	35.9	44.8 %
Gland Pharma Ltd	49,333	43.1	15.1 %

No bulk or block deals on record.

Ex-date	Action	Factor
2026-09-21	Dividend - Re 1 Per Share
2025-09-22	Dividend - Re 1 Per Share
2024-09-20	Annual General Meeting/Dividend - Re 1 Per Share
2023-09-22	Annual General Meeting/Dividend - Re 1 Per Share
2022-09-19	Annual General Meeting/Dividend - Rs 1.50 Per Share
2021-09-22	Annual General Meeting/ Dividend Rs 1 Per Share
2020-09-17	Annual General Meeting/Dividend - Re 1 Per Share
2019-09-12	Annual General Meeting/Dividend - Re 1 Per Share

Date	Type	What it says
2026-10-01	General Updates	Davaindia Stores Update for Q2FY27
2026-10-01	Acquisition	Acquisition of 39,228 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right ...
2026-10-01	Acquisition	Acquisition of 21,00,000 equity shares of M/s KMHP Ventures Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue
2026-10-01	Acquisition	Acquisition of 20,20,000 equity shares of M/s Curexis Ventures Private Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the ...
2026-09-30	Shareholder meeting	Voting results.

Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.

No short selling reported to NSE in our files.

Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.

EPS in the scrip is zero (4 trailing quarters)Loss making